NT-proBNP in severe chronic heart failure: Rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy

Franz Hartmann, Milton Packer, Andrew J S Coats, Michael B. Fowler, Henry Krum, Paul Mohacsi, Jean L. Rouleau, Michal Tendera, Alain Castaigne, Jürgen Trawinski, Ildiko Amann-Zalan, Silke Hoersch, Hugo A. Katus

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Background: Neither profiles nor prognostic value of cardiac N-terminal proBNP (NT-proBNP) have been prospectively evaluated in a sufficient number of patients with severe chronic heart failure (CHF) treated with carvedilol or placebo. Methods: Baseline and follow-up plasma concentrations of NT-proBNP were measured in the European part of the COPERNICUS Trial. This study enrolled patients with an ejection fraction <25% and symptoms of CHF at rest or on minimal exertion, equally randomized to placebo or carvedilol. Results: NT-proBNP concentrations were increased at baseline (mean±S.D.= 579±822 pmol/l, median=322.5 pmol/l) with a marked decrease during follow-up in the carvedilol, but not in the placebo group. One-year mortality rates were 3.9, 12 and 27.9% in the lower, middle and upper tertiles of NT-proBNP, respectively. When mortality was calculated separately in the placebo and carvedilol group, rates were 0.8, 6.3 and 19.1% in the carvedilol treated but 6.7, 17.9 and 36.9% in the placebo treated patients. Conclusions: NT-proBNP was a powerful predictor of subsequent all-cause mortality in patients with severe CHF. This marker should therefore be further evaluated for risk stratification and monitoring of therapy in CHF.

Original languageEnglish (US)
Pages (from-to)343-350
Number of pages8
JournalEuropean Journal of Heart Failure
Volume6
Issue number3
DOIs
StatePublished - Mar 15 2004

Fingerprint

Heart Failure
Placebos
Mortality
carvedilol
pro-brain natriuretic peptide (1-76)
Therapeutics

Keywords

  • Heart failure
  • Natriuretic peptides
  • Prognosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

NT-proBNP in severe chronic heart failure : Rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. / Hartmann, Franz; Packer, Milton; Coats, Andrew J S; Fowler, Michael B.; Krum, Henry; Mohacsi, Paul; Rouleau, Jean L.; Tendera, Michal; Castaigne, Alain; Trawinski, Jürgen; Amann-Zalan, Ildiko; Hoersch, Silke; Katus, Hugo A.

In: European Journal of Heart Failure, Vol. 6, No. 3, 15.03.2004, p. 343-350.

Research output: Contribution to journalArticle

Hartmann, F, Packer, M, Coats, AJS, Fowler, MB, Krum, H, Mohacsi, P, Rouleau, JL, Tendera, M, Castaigne, A, Trawinski, J, Amann-Zalan, I, Hoersch, S & Katus, HA 2004, 'NT-proBNP in severe chronic heart failure: Rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy', European Journal of Heart Failure, vol. 6, no. 3, pp. 343-350. https://doi.org/10.1016/j.ejheart.2004.01.009
Hartmann, Franz ; Packer, Milton ; Coats, Andrew J S ; Fowler, Michael B. ; Krum, Henry ; Mohacsi, Paul ; Rouleau, Jean L. ; Tendera, Michal ; Castaigne, Alain ; Trawinski, Jürgen ; Amann-Zalan, Ildiko ; Hoersch, Silke ; Katus, Hugo A. / NT-proBNP in severe chronic heart failure : Rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. In: European Journal of Heart Failure. 2004 ; Vol. 6, No. 3. pp. 343-350.
@article{ee3dc1bc744e4fbca9606de77a13eb8e,
title = "NT-proBNP in severe chronic heart failure: Rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy",
abstract = "Background: Neither profiles nor prognostic value of cardiac N-terminal proBNP (NT-proBNP) have been prospectively evaluated in a sufficient number of patients with severe chronic heart failure (CHF) treated with carvedilol or placebo. Methods: Baseline and follow-up plasma concentrations of NT-proBNP were measured in the European part of the COPERNICUS Trial. This study enrolled patients with an ejection fraction <25{\%} and symptoms of CHF at rest or on minimal exertion, equally randomized to placebo or carvedilol. Results: NT-proBNP concentrations were increased at baseline (mean±S.D.= 579±822 pmol/l, median=322.5 pmol/l) with a marked decrease during follow-up in the carvedilol, but not in the placebo group. One-year mortality rates were 3.9, 12 and 27.9{\%} in the lower, middle and upper tertiles of NT-proBNP, respectively. When mortality was calculated separately in the placebo and carvedilol group, rates were 0.8, 6.3 and 19.1{\%} in the carvedilol treated but 6.7, 17.9 and 36.9{\%} in the placebo treated patients. Conclusions: NT-proBNP was a powerful predictor of subsequent all-cause mortality in patients with severe CHF. This marker should therefore be further evaluated for risk stratification and monitoring of therapy in CHF.",
keywords = "Heart failure, Natriuretic peptides, Prognosis",
author = "Franz Hartmann and Milton Packer and Coats, {Andrew J S} and Fowler, {Michael B.} and Henry Krum and Paul Mohacsi and Rouleau, {Jean L.} and Michal Tendera and Alain Castaigne and J{\"u}rgen Trawinski and Ildiko Amann-Zalan and Silke Hoersch and Katus, {Hugo A.}",
year = "2004",
month = "3",
day = "15",
doi = "10.1016/j.ejheart.2004.01.009",
language = "English (US)",
volume = "6",
pages = "343--350",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - NT-proBNP in severe chronic heart failure

T2 - Rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy

AU - Hartmann, Franz

AU - Packer, Milton

AU - Coats, Andrew J S

AU - Fowler, Michael B.

AU - Krum, Henry

AU - Mohacsi, Paul

AU - Rouleau, Jean L.

AU - Tendera, Michal

AU - Castaigne, Alain

AU - Trawinski, Jürgen

AU - Amann-Zalan, Ildiko

AU - Hoersch, Silke

AU - Katus, Hugo A.

PY - 2004/3/15

Y1 - 2004/3/15

N2 - Background: Neither profiles nor prognostic value of cardiac N-terminal proBNP (NT-proBNP) have been prospectively evaluated in a sufficient number of patients with severe chronic heart failure (CHF) treated with carvedilol or placebo. Methods: Baseline and follow-up plasma concentrations of NT-proBNP were measured in the European part of the COPERNICUS Trial. This study enrolled patients with an ejection fraction <25% and symptoms of CHF at rest or on minimal exertion, equally randomized to placebo or carvedilol. Results: NT-proBNP concentrations were increased at baseline (mean±S.D.= 579±822 pmol/l, median=322.5 pmol/l) with a marked decrease during follow-up in the carvedilol, but not in the placebo group. One-year mortality rates were 3.9, 12 and 27.9% in the lower, middle and upper tertiles of NT-proBNP, respectively. When mortality was calculated separately in the placebo and carvedilol group, rates were 0.8, 6.3 and 19.1% in the carvedilol treated but 6.7, 17.9 and 36.9% in the placebo treated patients. Conclusions: NT-proBNP was a powerful predictor of subsequent all-cause mortality in patients with severe CHF. This marker should therefore be further evaluated for risk stratification and monitoring of therapy in CHF.

AB - Background: Neither profiles nor prognostic value of cardiac N-terminal proBNP (NT-proBNP) have been prospectively evaluated in a sufficient number of patients with severe chronic heart failure (CHF) treated with carvedilol or placebo. Methods: Baseline and follow-up plasma concentrations of NT-proBNP were measured in the European part of the COPERNICUS Trial. This study enrolled patients with an ejection fraction <25% and symptoms of CHF at rest or on minimal exertion, equally randomized to placebo or carvedilol. Results: NT-proBNP concentrations were increased at baseline (mean±S.D.= 579±822 pmol/l, median=322.5 pmol/l) with a marked decrease during follow-up in the carvedilol, but not in the placebo group. One-year mortality rates were 3.9, 12 and 27.9% in the lower, middle and upper tertiles of NT-proBNP, respectively. When mortality was calculated separately in the placebo and carvedilol group, rates were 0.8, 6.3 and 19.1% in the carvedilol treated but 6.7, 17.9 and 36.9% in the placebo treated patients. Conclusions: NT-proBNP was a powerful predictor of subsequent all-cause mortality in patients with severe CHF. This marker should therefore be further evaluated for risk stratification and monitoring of therapy in CHF.

KW - Heart failure

KW - Natriuretic peptides

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=10744223176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744223176&partnerID=8YFLogxK

U2 - 10.1016/j.ejheart.2004.01.009

DO - 10.1016/j.ejheart.2004.01.009

M3 - Article

C2 - 14987586

AN - SCOPUS:10744223176

VL - 6

SP - 343

EP - 350

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 3

ER -